Additive Manufacturing of Tablets

presentation by Christoph Hüls, Founder Additive Manufacturing of Tablets, Merck Innovation Center, Merck KGaA

Additive Manufacturing of Tablets has the potential to simplify the manufacturing of pills (tablets). Instead of a multistep complicated process, a three step process (mixing a powder formulation, printing the tablets in the printer and coating of the tablets) will lead to cost and time savings for customers.

In a strategic collaboration with AMCM GmbH, Merck is introducing the technology first for clinical trial supply, addressing the pain points of the pharmaceutical industry of very costly and long pharmaceutical drug development. The technology holds also the potential to decentralize the pharma production in the future by scaling the production with printers installed in the growing markets. The technology has therefore the potential to bring urgently needed medicines faster to patients.

program: https://www.3dpharmaprintingconference.com/speakers/

Interview

What drives you?

Innovation in the sense from idea to successful market introduction and the people driving it.

Why should the delegate attend your presentation?

The delegate will learn the challenges of the pharmaceutical industry in drug development and understand how 3D printing can contribute to bring medicine faster to patients.

What emerging technologies/trends do you see as having the greatest potential in the short and long run?

Battery technologies or in general energy storage. Technologies leading to less climate impact like artificial meat.

What kind of impact do you expect them to have?

Climate change is the challenge of our generation. btoh technologies will have an impact short and long term.

What are the barriers that might stand in the way?

Culture of societies and ignorant politicians.

“Special Quote”

3D printing is a technology area currently evolving with light speed impacting almost every single facette of our daily life, to name e few: food, housing, mobility and also medicinal treatment.

Christoph Hüls is leading the Merck Innovation Center project “Additive Manufacturing of Tablets”. Prior to this he was Head of Technology Foresight & Scouting and held positions in Merck’s business sectors Performance Materials and Healthcare in new business development, licensing, corporate venture capital and operational excellence in R&D. Before joining Merck, Christoph was CEO of Protagen AG. Previously he was responsible for portfolio and project management within the generics division of Novartis. Christoph began his career at Hoechst AG in different responsibilities in pharmaceutical and chemical R&D. He studied Biology and received his PhD from the Johannes-Gutenberg University in Mainz at the Institute of Immunology.

Merck, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2019, Merck generated sales of € 16.2 billion in 66 countries. Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials.

3D Pharma Printing Conference (February 4, 2021) addresses the latest developments in 3D printing medicines, as 3D printing is expected to find a place in certain niche medications and in personalised tablets. The topics approached include: New formulations for improved drug delivery; Patient-centric design / personalised medicine; Local manufacture / Simplified logistics; Faster pre-clinical evaluation of new drugs; Regulation & certification.

Cristoph is speaker at the 2021 edition of the conference.

Leave a Reply

Your email address will not be published. Required fields are marked *